

# Invitation

Janssen-Sponsored Milan Masterclass

## Virtual Milan PsA and PsO Masterclass

Hosted by

**Antonio Costanzo**

**Carlo Selmi**

**Humanitas Research Hospital, Milan, Italy**

**Thursday 2 December 2021**

**15:30–18:30 (CET)**

### Learning objectives

After attending this masterclass, participants should be able to:

- Identify the interactions and common pathways across immune-mediated inflammatory diseases
- Evaluate treatment targets and outcome measures for psoriasis and psoriatic arthritis
- Describe factors that influence treatment selection and management of patients with comorbidities
- Integrate the latest clinical safety and efficacy data and real-world data in the management of psoriasis and psoriatic arthritis
- Hypothesize how treatment optimization strategies could be utilized for optimal long-term patient outcomes

**janssen**  **Immunology**

PHARMACEUTICAL COMPANIES OF *Johnson & Johnson*

## Programme (all times in CET)

- 15:30–15:40 **Welcome and introduction**  
Carlo Selmi and Antonio Costanzo
- 15:40–15:55 **Pathophysiology and cytokine biology of PsA and PsO**  
Carlo Selmi and Antonio Costanzo
- 15:55–16:10 **Early diagnosis of PsA: clinical experience sharing**  
Carlo Selmi and Antonio Costanzo
- 16:10–16:15 **Q&A**
- 16:15–16:30 **Current treatment options in PsO**  
Antonio Costanzo
- 16:30–16:45 **Current treatment options in PsA**  
Carlo Selmi
- 16:45–17:00 **Q&A** (followed by a short break)
- 17:00–17:40 **Interactive case-based discussions: diagnosis, treatments, and comorbidity managements**  
Carlo Selmi, Antonio Costanzo, Alessandra Narcisi, and Nicoletta Luciano
- 17:40–17:55 **Beyond PsO: skin immune-mediated inflammatory diseases**  
Antonio Costanzo and Alessandra Narcisi
- 17:55–18:10 **Beyond PsA: rheumatoid arthritis, spondyloarthritis, and connective tissue diseases**  
Carlo Selmi and Nicoletta Luciano
- 18:10–18:20 **Interactive Q&A: participants' burning questions and cases**
- 18:20–18:30 **Close of meeting**  
Carlo Selmi and Antonio Costanzo

With the support of Janssen Pharmaceutical Companies  
of Johnson & Johnson in EMEA

Janssen Pharmaceutica NV  
Turnhoutseweg 30  
B-2340 Beerse, Belgium

Date of preparation: September 2021  
EM-72576